Life Sciences Archive » August, 2025

Life Sciences - August, 2025

263 articles

• Stewart Again Rebuffs Nat. Security In New Discretion Batch
• Pfizer Sued Over Depo-Provera Brain Tumor Risks
• 3rd Circ. Backs Walmart In Opioid Securities Disclosure Suit
• Data Undermines USPTO's 'Settled Expectations' Doctrine
• Calif. AG Puts Conditions On $24B Walgreens Deal
• Advice For 1st-Gen Lawyers Entering The Legal Profession
• Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe
• High Court E-Cig Ruling Opens Door For FDA Challenges
• Ill. Jury Sides With Ex-CTA Worker In Vax Bias Lawsuit
• House Dems Reintroduce Marijuana Legalization Bill Again
• Ex-NephroSant CEO Gets Docs Claim Tossed In Fee Row
• NeoGenomics Scores Win In Natera DNA Test Patent Suit
• Taxation With Representation: White & Case, Paul Weiss
• 3rd Circ. Agrees Natera Doesn't Owe $45M In False Ad Fight
• CBP, ITC Say Masimo Suit Over Apple Watch Ruling Misplaced
• Del. Judge Rejects J&J Unit's $12M Interference Claim
• 2nd Circ. Affirms Hedge Fund Win In $87M Short-Swing Suit
• Kimberly-Clark To Pay $40M Over Adulterated Surgical Gowns
• Local Gov'ts Seek Win In Suit Over HHS-Canceled Grants
• DOJ Seeks Kroger Patient Data In Opioid FCA Probe
• FTC Unpauses Administrative Case Over Insulin Prices
• Mylan Must Face Generic Drug Price-Fixing Claims In MDL
• Religion Didn't Drive Ex-CTA Worker's Vax Refusal, Jury Hears
• AstraZeneca Challenges Colo. Law Over Drug Pricing Rules
• J&J Unit Can't Shake $442M Loss In Catheter Antitrust Suit
• Fed. Circ. In July: Instability In IPR Requirements
• 1st Circ. OKs Terminating Ex-Pharma VP's Disability Benefits
• Bradley Arant Taps Parker Hudson Healthcare Atty In Atlanta
• Structuring Noncompetes In License And Collaboration Deals
• Sycamore Closes $24B Walgreens Deal, Replaces CEO
• Telehealth Co. Faces Investor Suit Over Revenue Reversal
• SC Ends Sandoz, Novartis Price-Fixing Claims For $2.4M
• Fed. Circ. Won't Upend Toss Of Flu Vaccine Injury Claim
• Coaching Cheerleading Makes Me A Better Lawyer
• HHS Says CDC Head Has Been Fired. She Says Otherwise.
• DOJ Throws Lifeline To J&J At 3rd Circ. After $1.6B FCA Loss
• Judge Unsure AI Drugmaker Investors Backed Retooled Suit
• MSN Warns Justices Of 'Double Standard' In Entresto Appeal
• 7 Ways To Fetch Patents In The World Of Working Animals
• Splenda Maker Knows It Contains Toxic Chemical, Scientist Says
• 9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool
• Scholars Tell High Court To Back Conversion Therapy Ban
• Boehringer Wins Another Zantac Cancer Trial In Ill.
• Baker Botts Adds 2 More Lateral Partners In NY
• Law School's Missed Lessons: How To Make A Deal
• Split 9th Circ. Upholds Oregon Pharmaceutical Reporting Law
• Ex-Genentech Worker Urges 9th Circ. To Revive ERISA Suit
• Healthcare Deals This Week: AbbVie, Royalty Pharma, BeOne
• AI Copyright Licensing Is Helping To Fuel Tech's Evolution
• Fed. Circ. Backs Original Filer In First-Ever Derivation Ruling
• Mich. AG Lambasts UMich For Halting Trans Youth Care
• Blacklist Suit Blocked By Illegal Biz Ties, Justices Told
• From Clerkship To Law Firm: 5 Transition Tips For Associates
• King & Spalding Hires Former CMS Litigation Leader In DC
• Frier Levitt Adds FDA Regulation Specialist Duo
• Foley Hoag Adds Healthcare Co-Leader From Manatt
• Eli Lilly Settles Feud With Clinics Over TM Infringement
• Medical Device Co. Eyes $400M Raise For Solana Treasury
• Fed. Circ. Overbroad In Hip Joint Implant Suit, High Court Told
• Sanofi Escapes Out-Of-State Claims In Conn. Zantac Lawsuit
• Radiology Co. Wants Arbitral Award Nixed Over 'Legal Fiction'
• Fired CTA Worker Faced Bias Over Vax Refusal, Jury Told
• 9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs
• Associates Can Earn Credibility By Investing In Relationships
• Cooley, Latham Lead $360M ScPharmaceuticals Acquisition
• Puzzling Out When Similar Insurance Claims Are Related
• Generic-Drugs Group Asks 9th Circ. To Nix Pay-For-Delay Law
• AbbVie Nabs Depression Drug From Gilgamesh In $1.2B Deal
• Pfizer Says FDA Blocked Tumor Warnings For Depo-Provera
• Texas, Fla. Want In On Abortion Medication Challenge
• USPTO Allows Discretionary Denials For 3-Year-Old Patents
• Chicago Feds Create New Healthcare Fraud Section
• Altria Unit Says FDA Stonewalled On Flavored E-Cig Approvals
• Ex-Pharma Exec Leaked Bankruptcy Deliberations, Suit Says
• Supplement Co. Says Insurer Failed To Pay $2.1M Claim
• SEC Sues 5 For Insider Trading Before Chinook-Novartis Deal
• A Shifting Trend In FDA Form 483 Disclosure Obligations
• House Oversight Chair Presses DOJ On Chinese Vape Surge
• Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
• NJ Judge Halts Ex-CEO's Sentencing After Habba Ruling
• Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling
• Marketer Who Eyed US Fentanyl 'Grand Lab' Gets 15 Years
• Cannabis Cos. Face $2.9M IT Judgment After Unable To Pay Attys
• UPenn Gene Therapy Patent Survives Sarepta's PTAB Challenge
• Del. Judge Outlines Misconduct Behind Amgen's $50M Relief
• Fertility Co. Says Deception Suit 'Mischaracterizes' Test
• GTCR Deal A 'Smokescreen' For Coatings Merger, FTC Says
• CVS, Drugmakers Illegally Inflated Insulin Prices, City Claims
• High Court Allows Trump Admin To Cancel $783M In NIH Grants
• Breaking Down The Proposed Hemp Bill
• Assessing Federal Securities Class Action Stats In '25 So Far
• Quilting Makes Me A Better Lawyer
• Masimo Targets CBP Over Latest Apple Watch Import Ruling
• Masimo's 'Empty Voting' Suit Against Founder Gets Green Light
• Talphera Beats Investors' Bid To Save Slogan Suit At 9th Circ.
• Feds Lose Bid To Seal In Vax Patent Case Against Moderna
• How Agentic AI Is Testing The Limits Of Patent Law
• Texas AG Threatens Suit Over Orgs. Mailing Abortion Pills
• Device Co. Pans FTC's Resistance To $945M Heart Valve Deal
• Fired Pharma Co. VP Must Arbitrate Sex Bias Claims
• State AGs Sidelined From Sandoz Price-Fixing Deal
• How To Prep For Potential Passage Of SAFER Banking Act
• Former J&J Atty Slams Sanctions Bid Over Bias Suit
• Biotech Replimune Faces Derivative Suit Over Trial Claims
• CVS PBM Overbilling Judgment Trebled To $289M
• NJ Judge Files Corrected Version Of Error-Filled Opinion
• 3D Systems Brass Sued Over Revenue Projections
• Sotera Urges 6th Circ. To Toss Investors' Toxic Gas Suit
• Lab Owner Gets 3 Years For $40M COVID-19 Test Fraud
• Novo Nordisk Gets Forfeiture Claims Cut From 401(k) Suit
• 21 AGs Push DEA To Schedule 'Designer Xanax'
• Panel Weighs Ga. High Court Ruling In Sham Donor Suit
• A Former PTAB Judge Weighs The End Of Remote Hearings
• Generic-Drug Makers To Pay $71M To End Price-Fixing Claims
• The Future Of Lab-Test Regs After FDA Rescinds Rule
• SDNY Ruling Reinforces Joint Steering Committee Obligations
• What 2 Profs Noticed As Transactional Law Students Used AI
• Fed. Circ. Backs PTAB Ax Of DexCom Glucose Patent Claims
• HHS Says Layoffs, Reorganization Are Within Its Authority
• 'Ketamine Queen' Takes Plea Deal In Matthew Perry Case
• Pharma Company Beats Investor Suit Over Drug Safety Claims
• Boehringer Long Ignored Zantac's Cancer Risks, Jury Hears
• Catching Up With Delaware's Chancery Court
• Akero Investor Suit Over Liver Drug Trials Permanently Tossed
• What Patent Claim 'Invalidity' Means In Different Forums
• Life Sciences Data Rivals Settle Trade Secrets Battle
• Most Ozempic, Wegovy Claims Survive MDL Dismissal Bid
• LabMD Fights Dinsmore's Bid To Toss Malpractice Suit
• DEA Asks Health Officials To Review Psilocybin Rescheduling
• BigLaw Settlements Should Not Spur Ethics Deregulation
• Stewart Issues Dozens More Discretionary Denial Decisions
• Life Spine Owes $9.5M In Implant Patent Suit, Jury Says
• How Big Pharma Has Responded To FTC Delisting Demands
• 2nd Circ. Says Sun Life Can't Nix Worker's Benefits Challenge
• $111.25M Del. Settlement Proposed For Cencora Opioid Suits
• Wholesalers Want Final OK For $51M AstraZeneca Settlement
• AbbVie's Key RICO Claims In Drug Cost Fraud Suit Survive
• Genentech Files Patent Suit Over Breast Cancer Biosimilar
• 5 Ways Lawyers Can Earn Back The Public's Trust
• Judge Says Patents In $50M Amgen Jury Loss Unenforceable
• OptumRx Flags Email Accidentally Sent To Opioid MDL Parties
• Armistice Capital Beats Derivative Suit In Chancery
• Amid IP Fight, Apple Restores Watch's Blood Oxygen Monitor
• Conn. Lab To Pay $1.25M In False Claims Settlement
• USPTO's AI Tool Redefines Design Patent Landscape
• Class Actions At The Circuit Courts: August Lessons
• AGs' Dermatology Price-Fixing Case Not A Copy, Judge Says
• Hiking Makes Me A Better Lawyer
• Eli Lilly To Put $1.3B Into Obesity-Focused Medicine Biz
• What Attys Want To Know About Lutnick's Harvard IP Threat
• Whoop's Health Tracker Accused Of Sharing Users' Data
• David Protein Tees Up Bid To Toss Ingredient Antitrust Suit
• Labcorp Wins ERISA Trial As Judge Cites Stronger Witnesses
• Wash. Court Allows Vacated Conviction DNA To Prove Rape
• Cassava Investors Get Class Certified In Alzheimer's Drug Suit
• Texas Woman Says Marine Laced Her Drink With Abortion Pills
• Suit Claims UPPAbaby Car Seats Asphyxiate Infants
• What US-India Trade Deal Will Mean For Indian Pharma
• Time For Full Disclosure Of Third-Party Funding In MDLs
• Fed. Circ. Throws Out $4.7M Verdict In DNA Patent Suit
• NC Businessman Nabs Early Exit From Investment Fraud Suit
• Law School's Missed Lessons: Negotiation Skills
• Judge, Terumo Attorney Spar Over 'Final Judgment' Case
• 9th Circ. Reverses Trade Secrets Striking In Biotech Suit
• Texas Says Eli Lilly Offered Nursing Services As Kickbacks
• Worker's Flu Shot Ruling Goes Too Far, 5th Circ. Dissent Says
• Biogen Says It Owes Nothing After $122M IP Royalties Mistrial
• AstraZeneca, Stockholders Far Apart In Merger Damages Tally
• Conflicting Developments In Homelessness Legal Landscape
• Bayer Bets $1.3B On Kumquat Cancer Drug Candidate
• AG Watch: Texas Embraces The MAHA Movement
• FTC Skeptical Of 'Partial' Sale For GTCR Merger Fix
• Roche Settles Trade Secrets Suit With Stanford And Profs
• Bar Exam Reform Must Expand Beyond A Single Updated Test
• The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult
• Abbott Shakes Suit Over Meta, Google Data Sharing For Now
• GTCR Says Sale, Market Nix FTC Med Tech Merger Concerns
• Aetna, CVS Want Lab's $21M Payment Suit Tossed For Good
• Judge Rules NYC Can Enforce Kava Cafe Shutdowns
• Apple Prevails In Heartbeat Patent Suit On Standing, Invalidity
• Location Data And Online Tracking Trends To Watch
• Judge OKs Becton Dickinson's $9M Investor Settlement
• SEC Says Biotech Investor Traded On Inside Info About Deal
• A Simple Way Courts Can Help Attys Avoid AI Hallucinations
• DOJ Consumer Branch's End Leaves FDA Litigation Questions
• Trump Admin Threatens To Take Harvard's Patents
• MSN Calls On Full Fed. Circ. To Rethink Double Patenting Rule
• How Patent Attys Can Limit 'Skinny Label' Risks In Ads
• GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal
• FTC Maintains Support For Right-To-Repair In Med Robot Case
• Trump EO Requires Appointee Oversight Of US Grantmaking
• NJ Nonprofit Says Foundation Trying To Take Over Business
• Pa. Pharmacy To Pay $825K To Resolve False Claims Case
• Iowa PBM Law Challengers Seek Wider Block At 8th Circ.
• Attys Seek Final OK Of $100M Walgreens Rx Cost Settlement
• Stewart Rejects 8 IPR Petitions While Overriding May Denial
• The Evolving Legal Landscape For THC-Infused Beverages
• Medical Tech Startup Heartflow's Upsized IPO Raises $317M
• Taxation With Representation: Latham, Alston & Bird, Orrick
• UK Litigation Roundup: Here's What You Missed In London
• HHS Wins Another Round In Medicare Drug Negotiation Battle
• BioNTech's Acquisition Of CureVac Ends COVID Vax Case
• BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd
• Michigan AG Fights Bid To Pause PBM Price-Fixing Suit
• Ex-Worker Sues Firm For Bias After Work On CDC Contract
• Novartis Faces $291M Trade Secrets Suit From Hedge Fund
• Anthem Seeks Exit From Lab's $3.8M Insurance Suit
• 2nd Circ. Axes Challenge To Medicare Drug Price Negotiations
• Rising Star: Goodwin's Laura Umbrecht Gulick
• Investors Back Cancer Ultrasound Tech Firm At $2.25B Value
• Fed. Circ. Affirms PTAB Ax Of Bone Fusion Device Patents
• NC Biz Court Bulletin: Divorce Dust-Ups And Judicial Rebukes
• Creating Botanical Art Makes Me A Better Lawyer
• 6th Circ. Rips 'Stalking Horse' Ploy In Drug Negotiation Suit
• Ga. Judges Weigh Birth Defect Ruling in Sterigenics Case
• Masimo Drops Founder Joe Kiani From 'Empty Voting' Suit
• Indivior Beats Investor Suit Over Opioid Drug Sales Forecasts
• Insulin Collusion Needn't Be 'Clever' To Exist, 2nd Circ. Says
• State AGs Want Final OK For $39M Apotex Price-Fixing Deal
• Judge OKs Addition Of Kenvue, Janssen To J&J Talc MDL
• Rising Star: Quinn Emanuel's Frank Calvosa
• FTC Challenges $945M Heart Valve Deal
• 2nd Circ. Backs J&J Spinoff In 'Rapid Release' Label Suit
• Novo Nordisk Lodges Suits Over 'Knockoff' Semaglutide Meds
• OptumRx Urges Panel To DQ Motley Rice In LA Opioid Suit
• Key Opioid Theory Actually Irrelevant, Drug Cos. Tell 4th Circ.
• Ex-USPTO Heads, Judges Oppose Anti-Patent Thicket Bill
• Stewart Won't Reconsider Her 1st Settled Expectations Denial
• Lead Kicked From Pharma Investor Case Over Rogue Emails
• A Free Exercise 'Blueprint' In Colo. Abortion Reversal Order
• The Legal Education Status Quo Is No Longer Tenable
• Rising Star: Baker McKenzie's Piotr Korzynski
• Teva Settles Claims Over Delayed Generic Asthma Inhalers
• 2nd Circ. Reinforces Consensus On Vacating Foreign Awards
• Fla. Biz Won't Sell Knockoff Weight Loss Drugs After AG Deal
• Pharma Startup Claims Lupin Stole Inhaler Trade Secrets
• Gibson Dunn, Wachtell Advise On $1.5B Vision Implant Deal
• Trump's Sons Back 'New America' SPAC's $300M IPO Filing
• MOVEit Data Breach MDL Advances With Slimmed Frame
• GTCR Says Buyer In Place For Potential FTC Divestiture Deal
• Feds Get 2nd Crack At Regeneron FCA Case After Key Ruling
• Chemical Group Says Fluoride Judge Got It Wrong
• Investors Say Novo Nordisk Misled Them Over Drug Demand
• Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case
• Rising Star: Keker's Bailey Heaps
• Barnes & Thornburg Adds Leader Of FDA Practices At 2 Firms
• Healthcare Investor Clinches $1.86B For 5th Credit Fund
• E-Discovery Quarterly: Rulings On Relevance Redactions
• Ex-FDA Chief Of Staff Joins Hogan Lovells' Pharma Team
• Meta Illegally Recorded Flo Users' Data, Calif. Jury Finds
• Wheeling & Appealing: Midyear Highlights For Every Circuit
• IP Owners Largely Win In Stewart's Newest Discretion Orders
• USPTO Tightens Rules On Patent Challengers' Arguments
• AGs Sue Trump Over 'Onslaught Of Pressure' On Trans Care
• En Banc 9th Circ. Backs LA Schools In Vax Mandate Fight
• States Urge High Court To Keep NIH Grant Funds Flowing
• Monthly Merger Review Snapshot
• How DOJ's New Data Security Rules Leave HIPAA In The Dust
• Section 1983 Has Promise After End Of Nationwide Injunctions
• OptumRx Moves To DQ Motley Rice In Utah Opioid Case
• Trump's 2nd Term Puts Merger Remedies Back On The Table
• J&J Unit's Catheter Rival Scores Injunction After $442M Win
• Patent Ambiguity Persists After Justices Nix Eligibility Appeal